Targeted therapies for MASH show progress, with pegozafermin leading in efficacy for fibrosis regression and disease resolution. New research highlights the effectiveness of targeted therapies for ...
Reducing liver fat has become a central target in the development of therapies for metabolic dysfunction–associated steatohepatitis (MASH), particularly as drug developers and regulators look for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results